Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
完整音频预览
0:00
0:00
#1
Landmark NHS Blood Test Trial for Multiple Cancers Falls Short of Primary Objective
具里程碑意義的英國國家醫療服務體系多種癌症血液檢測臨床試驗未達主要目標
#2
A pioneering blood test designed to detect over fifty types of cancer has failed to achieve its primary goal in a large-scale clinical trial involving approximately 142,000 NHS patients.
一項旨在檢測五十多種癌症的開創性血液測試，在一項涉及約 142,000 名英國國家醫療服務體系患者的大規模臨床試驗中，未能實現其主要目標。
#3
The results, unveiled at the American Society of Clinical Oncology's annual conference in Chicago, revealed that the Galleri test did not significantly reduce late-stage cancer diagnoses.
在芝加哥舉行的美國臨床腫瘤學會年會上揭曉的結果顯示，Galleri 測試並未顯著減少晚期癌症的診斷。
#4
Had the trial succeeded, it would have marked a transformative breakthrough in medical research methodology and early cancer detection worldwide.
若該試驗取得成功，它將在醫學研究方法論和全球早期癌症檢測領域標誌著一項變革性的突破。
#5
The study, which constitutes the world's first randomised controlled trial of a multi-cancer early detection test, enrolled 142,942 asymptomatic participants aged fifty to seventy-seven.
這項研究構成了全球首例針對多種癌症早期檢測測試的隨機對照試驗，招募了 142,942 名年齡介於 50 至 77 歲之間的無症狀受試者。
#6
Each participant underwent annual blood draws over three years while continuing to receive standard cancer screening.
每位參與者在持續接受標準癌症篩查的同時，在三年的時間裡每年進行抽血。
#7
Researchers had hypothesised that supplementing conventional screening with the Galleri blood test could shift cancer diagnosis to earlier, more treatable stages, thereby improving patient outcomes substantially.
研究人員曾假設，在傳統篩查中加入 Galleri 血液檢測可以將癌症診斷推向更早、更易治療的階段，從而顯著改善患者的預後。
#8
Doctor Julie Gralow, who serves as the chief medical officer and executive vice-president of the oncology society, cautioned against drawing overly simplistic conclusions.
擔任美國臨床腫瘤學會首席醫學官兼執行副總裁的朱莉·格拉洛博士警告，不要得出過於簡單化的結論。
#9
She acknowledged that while the data exhibited some encouraging trends toward tumour downstaging, the trial ultimately did not meet its predefined primary endpoint.
她承認，雖然數據在腫瘤降期方面呈現出一些令人鼓舞的趨勢，但該試驗最終未能達到其預設的主要終點。
#10
Not only did the test fail to achieve statistical significance in reducing late-stage diagnoses, but it also raised fundamental questions about the viability of current multi-cancer detection approaches.
這項測試不僅未能達到減少晚期診斷的統計顯著性，還引發了關於目前多癌檢測方法可行性的根本性疑問。
#11
One senior oncology delegate, who spoke to journalists on condition of anonymity, characterised the outcome far more bluntly.
一名要求匿名的資深腫瘤學代表在接受記者採訪時，對結果的評價更為直白。
#12
The delegate reportedly stated that the clinical trial had unequivocally flopped, describing the failure as clear and simple.
據報導，該代表表示臨床試驗已明確失敗，並形容這次失敗是顯而易見且不爭的事實。
#13
Such candid assessments underscore the growing scepticism among specialists regarding whether a single blood test can reliably revolutionise cancer diagnosis across dozens of malignancies.
如此坦率的評估凸顯了專家們對於單一血液檢測是否能可靠地徹底改變數十種惡性腫瘤診斷的日益增長的懷疑。
#14
Nevertheless, proponents of the technology argue that the trial's secondary findings warrant further investigation before definitive judgments are rendered.
儘管如此，該技術的支持者主張，試驗的次要發現值得在做出最終判斷之前進行進一步調查。